Background: Dofetilide is a new class III antiarrhythmic drug currently under investigation for the treatment of supraventricular arrhythmias in humans. Dofetilide have been previously shown to be highly effective in terminating and suppressing reentrant atrial flutter in the experimental canine crush-injury model, in which its antiarrhythmic efficacy was correlated with prolongation of wavelength and reduction in dispersion of refractoriness, effects not produced by the class IA antiarrhythmic drug quinidine. The purpose of this study was to evaluate the antiarrhythmic efficacy and mechanisms of action of dofetilide in an experimen tal model of atrial fibrillation.
Methods and Results: Dofetilide was administered intravenously to seven open-chest dogs with acute sustained atrial fibrillation induced by rapid atrial pacing for up to 4 hours. Mean atrial effective refractory period (ERP), dispersion of ERP, conduction velocity and wave length were determined by multipoint right atrial programmed stimulation and activation mapping using a 56-electrode mapping plaque on the right atrial free wall. Dofetilide pro longed average ERP by 22% from 104 ± 13 to 127 ± 15 ms (P < .001), prolonged maximum ERP by 11% from 129 ± 7 to 143 ± 10 (P < .003), had no effect on conduction velocity at 200 ms pacing cycle length, slowed conduction velocity by 16% from 0.89 ± 12 to 0.75 ± .17 ms at 150 ms pacing cycle length ( P < .001), increased wavelength by 20% from 93 ± 7 to 112 ± 9 mm ( P < .01), reduced dispersion of ERP by 24% from 11.4 ± 2.9 to 8.7 ± 2.3 (P = .016), and reduced the number of adjacent electrodes with ERP difference ≥20 ms by 67% from 18.4 ± 7.1 to 6.1 ± 4.2 (P < .001). Dofetilide reduced the number of excitation wavelets (total over three beats) entering the region of the mapping plaque by 38% from 5.0 ± .8 to 3.1 ± .4 (P < .002). Dofetilide terminated atrial fibrillation in all seven dogs at a mean of 3.4 ± 2.2 minutes into the loading infusion and prevented reinduction of atrial fibrillation in all seven dogs after completion of the loading infusion, while on maintenance infusion. Time to termination of atrial fibrillation correlated closely with change in ERP (r = 0.78, P = .036). Conclusions: Dofetilide was highly effective in terminating and suppressing sustained pac ing induced atrial fibrillation in this canine model. Time to termination of atrial fibrillation correlated with the degree of change in ERP produced by dofetilide. The mechanism of ter mination of atrial fibrillation by dofetilide appeared to be a progressive reduction and even tual extinction of re-entrant wavelets. The predominant electrophysiologic effects of dofetilide were prolongation of ERP and wavelength and a reduction in dispersion of refrac toriness. Dofetilide had little effect on conduction velocity in this model, except at very short pacing cycle lengths.
Falk RH, Pollak A., Singh SN, et al. Intravenous dofetilide. a class III antiarrhythmic agent, for the termination of atrial fibrillation or flutter. J Am Coll Cardiol29:385, 1997
2.
Rasmussen H., Dalrymple H., Allen M., Butrous G.Evolving experimental and clinical profile of dofetilide. In Electropharmacological Control of Cardiac Arrhythmias, Singh BN, Wellens HJJ, Hiraoka M, (eds) Futura Publishing, New York, pp. 551-568, 1994
3.
Suttorp MJ, Polak PE, van't Hof A., Rasmussen HS, Dunselman PH, Kingma JHEfficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol69:417, 1992
4.
Gwilt M., Arrowsmith JE, Blackburn KJ, Burges RA, Cross PE, Dalrymple HW, Higgins AJUK-68,798, a novel and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exper Ther256:318, 1991
5.
Gwilt M., Blackburn KJ, Burges RA, Higgins AJ, Milne AA, Solca AMElectropharmacology of dofetilide, a new class III agent, in anesthetized dogs. Eur J Pharmacol215:137, 1991
6.
Knilans TK, Lathrop DA, Varro A., Nanasi PP, Schwartz A.Rate and concentration dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fiber action potential duration and Vmax. Br J Pharmacol103:1568, 1991
7.
Tande PM, Bjornstad H., Yang T., Refsum H.Rate-dependent class III antiarrhythmic action, negative chronotropy and positive inotropy of a novel Ik blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol16:401, 1990
8.
Carmeliet E.Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther262:809, 1992
9.
Feld GK, Shahandeh-Rad F.Activation patterns in experimental canine atrial flutter produced by right atrial crush injury. J Am Coll Cardiol20:441, 1992
10.
Feld GK, Shahandeh-Rad F.Mechanisms of double potentials recorded during sustained atrial flutter in the canine right atrial crush-injury model. Circulation86:628, 1992
11.
Cha YM, Wales A., Wolf P., Shahrokni S., Sawhney N., Feld GKElectrophysiologic effects of the new class 3 antiarrhythmic drug dofetilide compared to the class la antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in Antiarrhythmic efficacy . J Cardiovasc Electrophysiol7:809, 1996
12.
Schoels W., Kuebler W., Yang H., Gough WB, El-Sherif N.A unified functional/anatomical substrate for circus movement atrial flutter: activation and refractory patterns in the canine right atrial enlargement model. J Am Coll Cardiol21:73, 1993
13.
Ohler A.Amos GJ, Wettwer E., Ravens U.Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for "reverse use dependent" block . Naunyn Schmiedebergs Arch Pharmacol349:602, 1994
14.
Vaughan Williams EMA classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol24:129, 1984
15.
Rensma PL, Allessie MA, LammersWJEP, Bonke FIM, Schalij MJ. Length of excitation wave and susceptibility to re-entrant atrial arrhythmias in normal conscious dogs. Circ Res62:395, 1988
16.
Wang Z., Page P., Nattel S.Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation . Circ Res71:271, 1992
17.
Spinelli W. , Hoffman BFMechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents. Circ Res65:1565, 1989
18.
Frame LH, Rhee ERSpontaneous termination of re-entry after one cycle or short nonsustained runs: role of oscillation and excess dispersion of refractoriness. Circ Res68:493, 1991
19.
Spach MS, Dolber PC, Heidlage JFInteraction of inhomogeneities of repolarization with anisotropic propagation in dog atria: a mechanism for both preventing and initiating re-entry. Circ Res65:1612, 1989
20.
Spach MSAnisotropic structural complexities in the genesis of re-entrant arrhythmias . Circulation84:1447, 1991
21.
Wijffels MC , Kirchhof CJ, Dorland R., Allessie MAAtrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation92:1954, 1995
